0610, 2021

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

View Press Release Triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech[1] New York, NY and Bordentown, NJ – October 6, 2021 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, and a company it founded, Caelum Biosciences, Inc. (“Caelum”), a biotechnology

2909, 2021

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

View Press Release Option exercise triggers upfront payment of approximately $150 million to Caelum shareholders, of which approximately $64 million is payable to Fortress Biotech[1] AstraZeneca intends to advance and accelerate the Phase 3 development of CAEL-101 for light chain (AL) amyloidosis HSR waiting period has expired for the acquisition of Caelum New York, NY and Bordentown, NJ – September 29, 2021 – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an

1106, 2021

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

View Press Release – Exploratory biomarker analyses suggest possible cardiac disease improvements and renal response – BORDENTOWN, N.J. & BOSTON, MA – JUNE 11, 2021 – Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, in combination with standard-of-care (SoC) therapy in patients with AL amyloidosis. The data, presented in two e-posters at the

1205, 2021

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

View Press Release – Accepted abstracts include new Phase 2 safety and tolerability data for CAEL-101 in AL amyloidosis – – Phase 3 studies of CAEL-101 in AL amyloidosis are underway – BORDENTOWN, N.J. & BOSTON, MA – MAY 12, 2021 – Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster presentation at

0103, 2021

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

View Press Release Bordentown, NJ – March 1, 2021 – Caelum Biosciences, Inc. (“Caelum”), a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases, today announced its collaboration with and support of the amyloidosis advocacy community as Amyloidosis Awareness Month begins. The campaign was created to spread awareness about this rare disease and its symptoms to help prompt earlier diagnosis for patients. In honor of the month and

0411, 2020

Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

– – Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis – – Phase 3 studies of CAEL-101 in AL amyloidosis are underway – BORDENTOWN, N.J. & BOSTON – November 04, 2020 11:55 AM Eastern Standard Time – (BUSINESS WIRE)–Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a first-in-class amyloid fibril targeted therapy, have been accepted for presentation at the

1409, 2020

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

– Positive long-term Phase 1a/1b data presented at the International Symposium on Amyloidosis (ISA) 2020 demonstrate prolonged overall survival (78% at 37 months) and durable organ response – – Phase 2 study met primary objective, supporting initiation of two parallel Phase 3 studies that will enroll ~370 AL amyloidosis patients – BOSTON & BORDENTOWN, N.J. – SEPTEMBER 14, 2020 – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Caelum Biosciences today announced the initiation of the Cardiac Amyloid

0212, 2019

Caelum Biosciences Granted Orphan Medicinal Product Designation from the European Commission for CAEL-101 for the Treatment of AL Amyloidosis

BORDENTOWN, NJ – December 2, 2019 – Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced that the European Commission (EC) has granted orphan medicinal product designation to CAEL-101 (previously known as 11-1F4), a light chain fibril-reactive monoclonal antibody (“mAb”), for the treatment of amyloid light chain (“AL”) amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by

3101, 2019

Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis

View Release – Collaboration provides opportunity to diversify Alexion’s clinical-stage rare hematology portfolio – – Caelum to receive up to $60 million for equity investment and option fee – – Alexion has option to acquire Caelum based on Phase 2 data – January 31, 2019 06:30 AM Eastern Standard Time BOSTON & NEW YORK–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and Caelum Biosciences today announced a collaboration to develop CAEL-101 for light

0412, 2018

Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting

View Press Release Phase 1b data confirm efficacy in AL Amyloidosis with two cardiac markers correlated with survival Preclinical data demonstrate the potential of using radiolabeled CAEL-101 for real-time imaging of human amyloidosis in vivo NEW YORK, NY – December 4, 2018 – Caelum Biosciences, Inc. (“Caelum”), a company focused on developing treatments for rare and life-threatening diseases, today announced additional global longitudinal strain (“GLS”) data from the Phase 1b study of